Your browser doesn't support javascript.
loading
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
Livingstone, E; Gogas, H; Kandolf-Sekulovic, L; Meier, F; Eigentler, T K; Ziemer, M; Terheyden, P A M; Gesierich, A H; Herbst, R A; Kähler, K C; Ziogas, D C; Mijuskovic, Z; Garzarolli, M; Garbe, C; Roesch, A; Ugurel, S; Gutzmer, R; Grob, J J; Kiecker, F; Utikal, J; Windemuth-Kieselbach, C; Eckhardt, S; Zimmer, L; Schadendorf, D.
Affiliation
  • Livingstone E; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, Essen, Germany.
  • Gogas H; First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Kandolf-Sekulovic L; Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.
  • Meier F; Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Dresden, Germany.
  • Eigentler TK; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Tübingen, Germ
  • Ziemer M; Department of Dermatology, University of Leipzig Medical Center, Leipzig, Germany.
  • Terheyden PAM; University Hospital Schleswig-Holstein, Lübeck, Germany.
  • Gesierich AH; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.
  • Herbst RA; HELIOS-Klinikum Erfurt, Erfurt, Germany.
  • Kähler KC; Department of Dermatology, Venerology, and Allergology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Ziogas DC; First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Mijuskovic Z; Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.
  • Garzarolli M; Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Garbe C; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Roesch A; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, Essen, Germany.
  • Ugurel S; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, Essen, Germany.
  • Gutzmer R; Department of Dermatology, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany; Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany.
  • Grob JJ; Aix-Marseille University, Timone Hospital (APHM), Marseille, France.
  • Kiecker F; Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Department of Dermatology and Venereology, Vivantes Hospital Neukölln, Berlin, Germany.
  • Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim,
  • Windemuth-Kieselbach C; Alcedis GmbH, Gießen, Germany.
  • Eckhardt S; Alcedis GmbH, Gießen, Germany.
  • Zimmer L; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, Essen, Germany.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, Essen, Germany. Electronic address: dirk.schadendorf@uk-essen.de.
Eur J Cancer ; 190: 112941, 2023 09.
Article in En | MEDLINE | ID: mdl-37482012
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Type of study: Clinical_trials Limits: Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Type of study: Clinical_trials Limits: Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Affiliation country: Country of publication: